NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) at the Forefront of Modernizing Immunology

June 27, 2019 14:41:12

Diversified clinical-stage immunology company INmune Bio (NASDAQ: INMB) is on a mission to develop novel immunotherapies that reprogram patients’ innate immune systems to enable them to fight cancer and Alzheimer’s disease. A recent article further discussing the company reads, “Innate is an immediate, nonspecific, initial response that serves as a first line of defense against infection and cancer. Most drug-development programs concentrate on the adaptive immune response and ignore innate immunity. INmune Bio harnesses the innate immune system with a targeted biomarker approach. . . . The company’s INKmune drug is a biologic therapy. INKmune primes NK cells to eliminate minimal residual disease, which is a major cause of cancer relapse and death. NK cells play a vital role in preventing cancer. Later this year, the company expects to begin enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer.”

To view the full article, visit http://nnw.fm/Qg6hm

About INmune Bio Inc.

INmune Bio Inc. (NASDAQ: INMB) is a publicly traded, clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that re-engineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com